United States President Donald Trump has signed an executive order allowing tariffs of up to 100 percent on certain patented drugs if pharmaceutical companies do not negotiate pricing deals with his administration. Companies that establish “most favored nation” pricing and build facilities in the U.S. will avoid tariffs, while others face increasing tariffs over four years. Critics warn these tariffs may drive up costs and jeopardize investments in U.S. biopharmaceutical manufacturing.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
